Richter, STADA sign distribution agreement for Pegfilgrastim

Initiatives

Hungarian drugmaker Gedeon Richter on Thursday said it had signed a license and distribution agreement with Germanyʼs STADA Arzneimittel for Richterʼs biosimilar Pegfilgrastim.

Under the agreement, STADA gets non-exclusive distribution rights for Pegfilgrastim in geographical Europe, while Richter retains its right to distribute and market the drug worldwide.

In addition to a payment made upon the signing of the contract, STADA will make further payments depending on the progress of the project, Richter said.

Pegfilgrastim is a pegylated recombinant, human granulocyte-colony stimulating factor and is used in adult patients for treatment of neutropenia, an illness that often accompanies cytotoxic chemotherapies and depicts a decrease in certain white blood cells. The active ingredient is a further development of Filgrastim, which STADA has been selling as a biosimilar since 2014.

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.

Support the BBJ

Environment